FOXP3 and GARP (LRRC32): the master and its minion

Michael Probst-Kepper1, Jan Buer2

Abstract
The transcription factor FOXP3 is essential for the development and function of CD4+CD25hiFOXP3+ regulatory T (Treg) cells, but also expressed in activated human helper T cells without acquisition of a regulatory phenotype. This comment focuses on glycoprotein-A repetitions predominant (GARP or LRRC32) recently identified as specific marker of activated human Treg cells, which may provide the missing link toward a better molecular definition of the regulatory phenotype.

Reviewers: Dr Jim Di Danto, Dr Benedita Rocha and Dr Werner Solbach.

Introduction

Proposed role of FOXP3 in self-tolerance
The maintenance of self-tolerance involves central and peripheral mechanisms, but the process of thymic negative selection is imperfect. Self-reacting clones that escape central tolerance are kept in check by a variety of peripheral tolerance mechanisms, in which the dominant tolerance exerted by CD4+CD25+ regulatory T (Treg) cells plays an important role. The development and function of Treg cells crucially depends on the forkhead/winged helix transcription factor FOXP3. This dependence is compellingly illustrated by the fact that loss of function of FOXP3 leads to the development of the fatal autoimmune lymphoproliferative disorder IPEX (immunodysregulation, polyendocrinopathy, and enteropathy, X-linked) syndrome [1,2]. Similarly, loss of function of FoxP3 in mice, either natural (scurfy) or recombinant, results in an analogous immune pathology due to a lack of Treg cells [3-5]. The dominant role of FOXP3 is further corroborated by the fact that the gain of function induced by ectopic expression in conventional CD4+CD25+ helper T (Th) cells leads to the acquisition of suppressor function and the induction of a partial regulatory phenotype in mice and humans [3,6-8].

Despite advances in our understanding of Treg-cell lineage commitment and function, gained mainly by the study of FoxP3 knock-out/knock-in mice [4,5,9-11], the dominant role of FOXP3 in the human system and its suitability as a bona fide marker of human Treg cells have been questioned [8,12-14].

Why should Treg cells need more than FOXP3?
The reasoning that more than FOXP3 is necessary for fully explaining the regulatory phenotype in humans is supported by several observations. First, T-cell receptor (TCR) stimulation of CD4+CD25-FOXP3- T cells leads to the induction of FOXP3 without interfering with the expression of effector cytokines such as interleukin-2 and interferon-γ [15-17]. Second, the expression of FOXP3 by conventional CD4+CD25- Th cells and even by Th lines and clones does not necessarily indicate the acquisition of suppressor function [8,12,17-19]. Third, and more specifically, it has recently been found that demethylation of a conserved FOXP3 intronic region may be a better marker for suppressor function than the differential expression of FOXP3 at the mRNA or protein level in Treg and Th cell clones [20]. Fourth, ectopic expression of FOXP3 in human Th cells does not lead to the establishment of a stable regulatory phenotype [8,12,21]. Finally, although the enhancement of FOXP3 expression by transforming growth factor-β1 (TGF-β1) in activated human CD4+CD25+ Th cells generates so-called induced Treg (iTreg) cells, this phenotype is rapidly lost [19,21,22]. Altogether, these observations suggest that more than FOXP3 is necessary for fully explaining the regulatory phenotype.

A plausible explanation for the qualitative and quantitative differences in the expression of FOXP3 in human Th and Treg cells, with their mutually exclusive effector
and regulatory functions, is the presence of a $T_{reg}$-specific higher-order regulatory network [13,14,23]. The possibility that $T_{reg}$-specific control mechanisms can maintain sustained high levels of FOXP3 and can control the regulatory function has been addressed only recently with the identification of the glycoprotein-$A$ repetitions predominant (GARP or LRRC32) receptor [21,24-28].

**Identification and characterization of GARP as a safeguard of FOXP3**

GARP was identified based on the analysis of gene expression profiling of $T_{reg}$ and $T_h$ cells following TCR stimulation, since TCR stimulation does lead to the induction of their mutually exclusive functions [21,24]. GARP is specifically induced in CD4$^+$CD25$^{hi}$FOXP3$^{hi}$ $T_{reg}$ cells and thus is a $T_{reg}$-specific activation marker [21,24-27]. Because the expression of GARP is up-regulated in FOXP3-transduced $T_h$ cells, GARP obviously depends on FOXP3, and this finding suggests a potential contribution to the regulatory phenotype [21,29].

The function of GARP has been elucidated by ectopic over-expression in human alloantigen-specific $T_h$ cells and down-regulation of GARP in human antigen-specific $T_{reg}$ cells [21,29]. Retroviral over-expression of GARP in $T_h$ cells, after some rounds of TCR stimulation, leads to an efficient and stable reprogramming/transdifferentiation of the established effector toward the regulatory program. This finding is associated with constitutive expression of FOXP3, the β-galactoside binding protein lectin, galactoside-binding, soluble, 3 (LGALS3) [8,30], and the cysteine-endoprotease legumain (LGMAPN) [8] and with an extended $T_{reg}$ signature with suppression of effector cytokine production and acquisition of regulatory functions similar to those of $T_{reg}$ cells [21,29]. Thus, a FOXP3-regulating gene has been identified in the human system, and this finding suggests that the GARP signaling pathway may have direct therapeutic applications [28,31] similar to those that have been described for CD83 in the murine system [32].

In contrast, lentiviral down-regulation of GARP in human alloantigen-specific $T_{reg}$ cells by specific small interfering RNA (siRNA) substantially impairs suppressor function and FOXP3 expression that is associated with impaired induction of CD83 and CD27, both known to regulate FOXP3 [21,32,33]. More striking is the fact that similar changes are induced by the down-regulation of FOXP3 in $T_{reg}$ cells, a finding that provides compelling evidence for a GARP-FOXP3 positive feedback loop in $T_{reg}$ cells. Because this feedback loop seems to be interrelated with other FOXP3-regulating systems such as CD83 and CD27, the existence of a higher-order regulatory network as discussed recently by Hori [13], can be speculated (Figure 1a).

Thus, GARP is a specific marker of activated $T_{reg}$ cells and can explain the qualitative and quantitative differences in FOXP3 expression and function in $T_{reg}$ cells and $T_h$ cells. Lack of GARP expression further differentiates and explains the transient nature of TGF-$β$-induced iT$_{reg}$ cells [19], suggesting that natural and iT$_{reg}$ cells may represent alternative differentiation stages of suppressor cells [21,26]. In line with these observations, a specifically hypomethylated region in intron 1 of GARP and two differentially methylated regions with enhancer functions in $T_{reg}$ cells have recently been characterized. These findings have identified an epigenetic basis for the lineage-specific difference in GARP expression [34].

**GARP brings latent TGF-β into a new game**

Members of the TGF-$β$ family are pleiotropic cytokines with crucial functions in differentiation, morphogenesis, and immune homeostasis. Their function in immune homeostasis is evidenced by the fact that dysregulation of TGF-$β$ functions is associated with autoimmunity [35]. Like many other cell types, human $T_{reg}$ and $T_h$ cells can secrete latent TGF-$β$ [20,36]. However, latency-associated peptide (LAP) prevents the activation of latent TGF-$β$ toward the active mature TGF-$β$ [37]. The selective induction of LAP and the activation of active TGF-$β$ upon TCR stimulation has been reported only for human $T_{reg}$ cells and clones [20,37,38]. This finding further explains the TGF-$β$ specific transcriptional signature and detection of expression of phosphorylated SMAD2 in $T_{reg}$ cells of human and murine origin [20,23,37,39]. Moreover, specific up-regulation of LAP on activated human $T_{reg}$ cells has been shown to allow improvements in the purity of $T_{reg}$ cell isolation procedures by separating activated LAP$^+$FOXP3$^+$ $T_{reg}$ cells from contaminating effector LAP$^-$FOXP3$^{+lo}$ $T_h$ cells [38]. Thus, besides being a marker of activated $T_{reg}$ cells in complex with LAP, TGF-$β1$ is an important modulator of FOXP3 expression [19,21,40], and a potential mediator of infectious tolerance by its action in converting FoxP3$^+$ murine CD4$^+$ $T$ cells into functional FoxP3$^+$ iT$_{reg}$ cells [41].

The issue of cell-surface binding of LAP/latent TGF-$β$ on human $T_{reg}$ cells has been addressed only recently with the identification of GARP as a receptor of this complex [26,27]. Therefore, two important regulatory circuits of $T_{reg}$ cells come together: the GARP-FOXP3 feedback loop and the autocrine TGF-$β$ loop (Figure 1b). With that, the potential synergy of many of the $T_{reg}$ signature components that are essential for the regulatory properties that have been ascribed to TCR activation, interleukin-2, TGF-$β$, and FOXP3 itself [20,23] could be explained by this particular spatiotemporal interplay of interrelated signaling systems on $T_{reg}$ cells.
Figure 1 GARP as safeguard of the regulatory phenotype. (A) Qualitative (lineage-specific) and quantitative (dose-effect) differences in FOXP3 expression in human helper T cells (Th, upper panel) and regulatory T cells (Treg, lower panel) are due to lineage-specific methylation of the respective loci (indicated by black dots) and thus the expression of the genes FOXP3 and GARP. In human Treg cells, a positive feedback loop has been found between GARP and FOXP3; this feedback loop is interrelated with the FOXP3-enhancing molecules indicated. Phosphorylation of LGALS3 (indicated by a P) has been reported to be essential for the FOXP3-regulating function [21]. GARP is a receptor for LAP/latent TGF-β [26,27]. T-bet (T-box expressed in T cells), GATA3 (GATA-binding protein 3), RORγ (retinoic-related orphan receptor gamma) represent transcription factors of Th1, Th2, and Th17 cells. (B) Implications for human and murine T cells, respectively, of the autocrine and paracrine effects of GARP and Nrp1 surface-bound LAP/latent TGF-β after activation of TGF-β. The TGF-β signature phospho-SMAD2 (pSMAD2) has been observed in human (GARP+) and murine (Nrp1+) Treg cells. Paracrine effects include the generation of infectious tolerance. (C) Structural composition of the LAP/latent TGF-β binding proteins Nrp1 and GARP (LRR, leucine-rich repeat domain; CUB, complement subcomponents C1r/C1s domain; F5/8, coagulation factor domain; MAM, meprin, A5, and receptor protein-tyrosin phosphatase μ domain; TM, transmembrane region; L, leader peptide). NIP (Nrp1 interacting protein) is a Nrp1 binding protein involved in the regulation of Nrp1-mediated signaling as a molecular adapter [48].
Perspective: does Nrp1 represent a functional homologue of GARP in murine Treg cells?

The identification of GARP as a receptor for LAP/latent TGF-β opens speculation about a potential common denominator. The reason for such speculation is that neuropilin 1 (Nrp1), which has been characterized as a marker of CD4+CD25+ Treg cells in mice that enhances Treg cell/dendritic cell contact during antigen recognition [42,43], has also been characterized as a receptor for LAP/latent TGF-β [39]. Moreover, murine sorted Nrp1+ T cells capture soluble Nrp1 (applied as a constant fragment [Fc]-fusion protein), and the captured Nrp1 increases their ability to bind LAP/TGF-β1. Such coated T cells acquire strong regulatory activity [39]. Thus, Nrp1 is a TGF-β1 receptor that, unlike GARP [27], also activates the latent form of TGF-β1.

The structural differences between GARP, a Toll-like receptor homologue with leucine-rich repeats, and the multi-domain protein Nrp1, a receptor for class-3 semaphorin-family proteins and vascular endothelial growth factor (Figure 1c) [44], necessitate further biochemical and molecular analyses to identify specific binding interactions and potentially associated molecules. The issue of GARP expression in murine Treg cells at the protein level remains to be elucidated.

Discussions

Open Questions Concerning the Function of GARP

Because GARP is constitutively expressed on platelets [26,45], and because a potential function of GARP on thrombus formation has recently been reported [46], important questions about GARP signaling and parallel function in platelets compared to Treg cells could be considered. Concerning the dependence of GARP expression on FOXP3 as described above, it has been reported that FOXP3 is expressed by human and murine megakaryocytes [47]. Therefore, the thrombocytopenia and platelet abnormalities experienced by some patients with IPEX syndrome can be explained by loss of function of FOXP3 [47]; however, this explanation would suggest a concomitant impairment of GARP expression and function on IPEX platelets, an impairment that has not yet been shown.

A controversial issue is the potential suppressor function of GARP, suggested recently [24], because platelets as a natural source of GARP-expressing cells do not function as suppressor cells [21]. Therefore, differences in the function of GARP in platelets and Treg cells can be suggested. This question is important for the potential design of GARP-selective drugs that can specifically target only Treg cells and not platelet functions. As of now, neither the ligand nor the signaling system or potential co-receptor(s) of GARP has been identified, and identifying them is the most important challenge for the future.

Conclusions

The identification of GARP as a lineage-specific key receptor of human activated Treg cells, which is in part controlled by lineage-specific hypomethylation of the GARP locus, the characterization of a GARP-FOXP3 positive feedback loop that safeguards FOXP3 expression in Treg cells, and the binding of LAP/latent TGF-β to GARP provide a conceptual framework for a new molecular definition of the regulatory program. If GARP is a receptor for the well-known immune modulator TGF-β on human Treg cells, and if Nrp1 plays this same role on murine Treg cells, then this similarity might explain the similarities in the TGF-β signatures that have been observed in Treg cells in both species. The surface binding and activation of TGF-β have obvious implications for infectious tolerance. Complete elucidation of the GARP/GARP-ligand signaling system in Treg cells and platelets is an important challenge and a prerequisite for the future development of strategies and tools for inducing or inhibiting Treg cells in chronic infection, tumor immunotherapy, autoimmune diseases, and transplantation.

List of abbreviations used

GARP: glycoprotein-A repetitions predominant; IPEX: immune dysregulation, polyendocrinopathy, enteropathy, X-linked; iTreg cells: induced regulatory T cells; LAP: latency-associated peptidase; Nrp1: neuropilin 1; SMAD: Sma- and Mad-related protein 2; TCR: T-cell receptor; TGF-β: transforming growth factor-β; Tδ cells: helper T cells; Treg cells: regulatory T cells.

Reviewers’ comments

Reviewer’s report 1

Reviewer 1: Dr. Jim Di Santo, Cytokines and Lymphoid Development Lab, Institut Pasteur, Paris, France

Reviewer’s comment: I have read your comment for Biology Direct entitled “FOXP3 and GARP (LRRC32): the master and its minion”. I find this comment to be interesting and suitable for publication in Biology Direct. I do not have any specific comments for web publication.

Reviewer’s report 2

Reviewer 2: Dr. Benedita Rocha, Institut National de la Santé et de la Recherche Médicale (INSERM) U591, Institut Necker, France

Reviewer’s comment: Regulatory cells have a fundamental role in many disease processes, and extensive experimental and clinical data indicate that tools preventing or increasing regulatory function will have a fundamental therapeutic role. While FOXP3 expression generally correlates with regulation in the mouse, this is not so in human T cells. This comment reviews a
fundamental aspect, the factors besides FOXP3 expression that ensure the induction of a stable regulatory function on human cells, their correlation with FOXP3 regulation and their possible mechanisms of action. I found the topic actual and important, the comment clear and comprehensive and strongly support publication.

**Reviewer’s report 3**

**Reviewer 3: Dr. Werner Solbach, Institute for Medical Microbiology and Hygiene, University Lübeck, Germany**

Reviewer’s comment: The ms. deals with the connectivity of FOXP3 and “glycoprotein - A repititions predominant receptor (GARP or LRRC32) in the context of the functioning of regulatory T cells (Tregs). This topic is of great relevance in the context of clarifying the equivilocal role of FOXP3 and its partners for explanation of regulatory T cell circuits. It is clear that not only FOXP3 or GARP alone, but also latently activated TGF-β is crucial for the suppressive activity of Treg cells. The authors now very nicely bring together the GARP - FOXP3 regulatory circuit with the autocrine TGF-β loop which helps to explain many Treg features. In their perspective, they also try to open thoughtful avenues how to bring together (human) GARP with its possible functional homologue in mice, neuropilin 1. In summary, they present a valuable conceptual framework for understanding the regulatory program in the T cell reactivity system and beyond. The ms. is well written and easy to understand. I recommend publication in *Biology Direct*.

**Acknowledgements**

Michael Probst-Kepper was supported by grants from the VolkswagenStiftung (I/73 234) and the Deutsche Forschungsgemeinschaft (PR554/2).

**Author details**

1 Institute for Microbiology, Immunology and Hygiene, Stadisches Klinikum Braunschweig gGmbH, Braunschweig, Germany. 2 Institute for Medical Microbiology, University Hospital Essen, Essen, Germany.

**Authors' contributions**

MPK and JB both were involved in drafting of the manuscript and approved the final version to be published.

**Competing interests**

The authors declare that they have no competing interests.

Received: 27 January 2010 Accepted: 5 February 2010 Published: 5 February 2010

**References**

1. Ziegler SF: FOXP3: Of Mice and Men. Annu Rev Immunol 2006, 24:209-226.
2. Gambineri E, Torgerson TR, Ochs HD: Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. *Curr Open Rheumatol* 2003, 15:430-435.
3. Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. *Nat Immunol* 2003, 4:337-342.
4. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY: Regulatory T cell lineage specification by the forkhead transcription factor foxp3. *Immunity* 2005, 22:329-341.
5. Lin W, Haribhai D, Reiland L, Huang Z, Carlson M, Williams C, Chatila T: Regulatory T cell development in the absence of functional Foxp3. *Nat Immunol* 2007, 8:359-368.
6. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. *Science* 2003, 299:1057-1061.
7. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol* 2003, 4:350-356.
8. Ocklenburg F, Moharregh-Khiabani D, Geffers R, Janke V, Pfoertner S, Garritsen H, Groebe L, Klemmever D, Dittmer K, Weiss S, Buer J, Probst-Kepper M: UBD, a downstream element of FOXP3, allows the identification of LAGAL3, a new marker of human regulatory T cells. *Lab Invest* 2006, 86:724-737.
9. Wan YY, Flavell RA: Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. *PNAS* 2005, 102:5126-5131.
10. Williams LM, Rudensky AY: Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. *Nat Immunol* 2007, 8:277-284.
11. Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, Ziegler SF, Roncarolo MG, Leving MK: The role of 2 FOXP3 isoforms in the generation of human CD4 Tregs. *J Clin Invest* 2005, 115:3276-3284.
12. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Leving MK: Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. *Int Immunol* 2007, 19:345-354.
13. Francois V, Ottaviani S, Renkvist N, Stocks J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, Bruggen van der P, The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells. *Cancer Res* 2009, 69:4335-4345.
14. Wang F, Ioan-Facsinay A, Voort van der El, Huizinga TW, Toes RE: Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. *Eur J Immunol* 2008, 39:925-927.
15. Gavin MA, Torgerson TR, Houston E, delRosso P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD, Rudensky AY: Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. *Proc Natl Acad Sci USA* 2006, 103:6659-6664.
16. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Leving MK: Identification of LGALS3, a new marker of human regulatory T cells. *Nat Med* 2005, 11:330-336.
17. Kuchroo VK, Ting JP, Antonchick AA, Jacobson KA, Grunstein MM, Weiss S: GARP: a key receptor controlling FOXP3 in human regulatory T cells. *J Biol Chem* 2005, 280:13433-13437.
18. Takaki H, Ichiyama K, Koga K, Chinen T, Takaesu G, Sugiyama Y, Kato S, Yoshimura A, Kobayashi T: Induction of FOXP3 expression in naive human CD4+ T cells. *Eur J Immunol* 2007, 37:129-138.
19. Tran DG, Ramsey H, Shevach EM: Induction of FOXP3 expression in naive human CD4+FOXP3- T cells by T cell receptor stimulation is TGF(beta)-dependent but does not confer a regulatory phenotype. *Blood* 2007, 110:2983-2990.
20. Stocks J, Fink W, Francois V, Connerette T, de Smet C, Knoop L, Bruggen van der P, Couille PG, Lucas S: Comparison of stable human Treg and Th clones by transcriptional profiling. *Eur J Immunol* 2009, 39:869-882.
21. Probst-Kepper M, Geffers R, Kröger A, Viegas N, Erck C, Hecht HJ, Lündorf H, Roubin R, Moharregh-Khiabani D, Wagner K, Ocklenburg F, Jero A, Garritsen H, Artiska TP, Kekäläinen E, Buring Y, Hausser J, Buer J, Weiss S: GARP: a key receptor controlling FOXP3 in human regulatory T cells. *J Immunol* 2009, 182:1343-1357.
22. Takaki H, Ichiyama K, Koga K, Chinen T, Takaseu G, Sugiyama Y, Kato S, Yoshimura A, Kobayashi T: STAT6 inhibits TGF-(b)-mediated FOXP3 induction through Direct Binding to the FOXP3 Promoter, Which Is Reverted by Retinoic Acid Receptor. *J Biol Chem* 2008, 283:14955-14962.
23. Hill JA, Feurer M, Tash K, Hashimoto S, Perez J, Melamed R, Mathis D, Benoist C: Foxp3 Transcription-Factor-Dependent and -Independent Regulation of the Regulatory T Cell Transcriptional Signature. *Immunity* 2007, 27:786-800.
24. Wang R, Wan Q, Kozhaya L, Fuji H, Unutmaz D: Identification of a Regulatory T cell specific Cell Surface Molecule that Mediates
Suppressive Signals and Induces Foxp3 Expression. PloS One 2008, 3: e27705.
25. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D: Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. PNAS 2009, 106:13439-13444.
26. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM: GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009, 106:13445-13450.
27. Stocks J, Colau D, Coulié PG, Lucas S: Membrane protein GARP is a receptor for latent TGF-β1 on the surface of activated human Treg. Eur J Immunol 2009, 39:3312-3322.
28. Probst-Kepper M, Kröger A, Gamitsen HSP, Buer J: Perspectives on Regulatory T Cell Therapies. Transfus Med Hemother 2009, 36:302-308.
29. Probst-Kepper M, Balling R, Buer J: FOXP3: Required but Not Sufficient. The Role of GARP (LRRC32) as a Safeguard of the Regulatory Phenotype. Curr Mol Med 2010.
30. Pfoertner S, Jeon A, Probst-Kepper M, Guzman CA, Hansen W, Westendorf AM, Toepfer T, Schrader AJ, Franzke A, Buer J, Geffers R: Signatures of Human Regulatory T Cells: An Encounter with Old Friends and New Players. Genome Biology 2006, 7:R54-1-R54-18.
31. Tran DQ, Shevach EM: Therapeutic potential of FOXP3 regulatory T cells and their interactions with dendritic cells. Hum Immunol 2009, 70:29-49.
32. Reinwald S, Wethe C, Westendorf AM, Breloer M, Probst-Kepper M, Fleischer B, Steinkasserer A, Buer J, Hansen W: CD83 Expression in CD4+ T Cells Modulates Inflammation and Autoimmunity. J Immunol 2008, 180:5890-5897.
33. Yang ZZ, Novak AJ, Ziemer SC, Witzig TE, Ansell SM: CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory activity in intratumoral CD4+CD25+ T cells. Blood 2008, 110:2537-2544.
34. Schmid C, Klug M, Boeld TJ, Andreessen R, Hoffmann P, Edinger M, Rehli M: Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res 2009, 19:1165-1174.
35. Wan YY, Flavell RA: TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol 2009, 29:647-659.
36. Levings MK, Sangregorio R, Sartorana C, Moschin AL, Battaglia M, Orban PC, Roncarolo MG: Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 regulatory cells. J Exp Med 2002, 196:1335-1346.
37. Nakamura K, Katanami A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W: TGF-beta1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004, 172:834-842.
38. Tran DQ, Andersson J, Hardwick D, Bebris L, Ille GG, Shevach EM: Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 2009, 113:5129-5133.
39. Glinka J, Prud’homme GJ: Neuropilin-1 is a receptor for transforming growth factor-β1, activates its latent form, and promotes regulatory T cell activity. J Leukoc Biol 2008, 84:302-310.
40. Fantini MC, Becker C, Monteleone G, Pallone F, Galli PR, Neurath MF: Cutting Edge: TGF-beta Induces a Regulatory Phenotype in CD4+CD25+ T Cells through Foxp3 Induction and Down-Regulation of Smad7. J Immunol 2004, 172:5149-5153.
41. Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ, Shevach EM: CD4 FoxP3 regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 2008, 205:1975-1981.
42. Bruder D, Probst-Kepper M, Westendorf AM, Geffers R, Beiser J, Lossers K, von Boehmer H, Buer J, Hansen W: Frontline: Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004, 34:623-630.
43. Sarris M, Andersson KG, Randow F, Mayr L, Betz AG: Neuropilin-1 Expression on Regulatory T Cells Enhances Their Interaction with Dendritic Cells during Antigen Recognition. Immunity 2008, 28:402-413.
44. Greten F, Klagesmünk M: Neuropilins: Novel Targets for Anti-Angiogenesis Therapies. Cell Adh Migr 2007, 1:56-61.
45. Macaulay IC, Tijssen MR, Thijssen-Timmer DC, Guusnato A, Steward M, Burns P, Langford CF, Ellis P, Dudbridge F, Zwaagjes JJ, Watkins NA, Schoot van der CE, Ouwehand WH: Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood 2007, 109:3260-3269.
46. O’Connor N, Salles I, Cvejic A, Watkins NA, Walker A, Gamer S, Macaulay IC, Steward M, Zwaagjes J, Bray S, Dudbridge F, de Bono B, Goodall AH, Deckmyn H, Sempere DL, Ouwehand WH: Bioinformatics: Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood 2008, 113:4754-4762.
47. Bernard JJ, Seweryniak KE, Konisli AD, Spinnelli SL, Blumberg N, Francis CW, Taubman MA, Palmi J, Phipps RP: Foxp3 Regulates Megakaryopoiesis and Platelet Function. Arterioscler Thromb Vasc Biol 2009, 29:1874-1882.
48. Cai H, Reed RR: Cloning and Characterization of Neuropilin-1-Interacting Protein: A PSD-95/Olg/ZO-1 Domain-Containing Protein That Interacts with the Cytoplasmic Domain of Neuropilin-1. J Neurosci 1999, 19:6519-6527.

doI:10.1186/1745-6150-5-8
Cite this article as: Probst-Kepper and Buer: FOXP3 and GARP (LRRC32): the master and its minion. Biology Direct 2010 5:8.